NCT04325503View on ClinicalTrials.gov

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 8, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Parkinsonian Signs in Older Persons
Interventions
DRUG

carbidopa

carbidopa and carbidopa-levodopa standard treatment

Trial Locations (1)

48105

Functional Neuroimaging, Cognitive, and Mobility Lab, University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Michigan

OTHER

NCT04325503 - Neurobiological Drivers of Mobility Resilience: The Dopaminergic System | Biotech Hunter | Biotech Hunter